Despite numerous setbacks and poor execution, Savient still has a strong product soon to see a favorable situation.. Let's not forget big pharma is still out there, desperately looking for (revenue) acquisition candidates. Savient still fits the bill.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.